Hilltop Holdings Inc. Has $346,000 Position in Novo Nordisk A/S (NVO)

Share on StockTwits

Hilltop Holdings Inc. reduced its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 4.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,503 shares of the company’s stock after selling 366 shares during the quarter. Hilltop Holdings Inc.’s holdings in Novo Nordisk A/S were worth $346,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Roundview Capital LLC increased its position in Novo Nordisk A/S by 1.3% during the 4th quarter. Roundview Capital LLC now owns 16,870 shares of the company’s stock valued at $777,000 after buying an additional 210 shares in the last quarter. Garrison Financial Corp increased its position in Novo Nordisk A/S by 2.5% during the 4th quarter. Garrison Financial Corp now owns 12,510 shares of the company’s stock valued at $576,000 after buying an additional 300 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its position in Novo Nordisk A/S by 2.4% during the 4th quarter. Edmond DE Rothschild Holding S.A. now owns 13,702 shares of the company’s stock valued at $632,000 after buying an additional 324 shares in the last quarter. Advisor Partners LLC increased its position in Novo Nordisk A/S by 2.7% during the 4th quarter. Advisor Partners LLC now owns 12,634 shares of the company’s stock valued at $582,000 after buying an additional 338 shares in the last quarter. Finally, Dorsey & Whitney Trust CO LLC increased its position in Novo Nordisk A/S by 6.7% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 6,727 shares of the company’s stock valued at $310,000 after buying an additional 420 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Shares of NVO stock opened at $52.63 on Thursday. The stock has a market capitalization of $128.60 billion, a PE ratio of 20.88, a PEG ratio of 2.48 and a beta of 0.59. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $52.83.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Friday, February 1st. The company reported $0.54 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.03). The firm had revenue of $4.55 billion during the quarter, compared to analyst estimates of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. Sell-side analysts anticipate that Novo Nordisk A/S will post 2.55 EPS for the current fiscal year.

NVO has been the topic of several recent analyst reports. Handelsbanken lowered Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 target price on the stock. in a research report on Monday, February 4th. UBS Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Sunday, December 2nd. Pareto Securities raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, November 26th. Deutsche Bank reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, December 10th. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $52.00 target price on the stock in a research report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. Novo Nordisk A/S presently has an average rating of “Hold” and a consensus target price of $52.31.

WARNING: This news story was originally posted by Zolmax and is owned by of Zolmax. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://zolmax.com/investing/hilltop-holdings-inc-has-346000-position-in-novo-nordisk-a-s-nvo/2979929.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity.

Featured Story: Why do companies issue stock splits?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SPINDLE  Reaches Market Capitalization of $2.12 Million
SPINDLE Reaches Market Capitalization of $2.12 Million
MediBit Trading 32.3% Higher  Over Last 7 Days
MediBit Trading 32.3% Higher Over Last 7 Days
Clovis Oncology  Expected to Announce Earnings of -$1.80 Per Share
Clovis Oncology Expected to Announce Earnings of -$1.80 Per Share
BUDDY Price Down 36.7% Over Last 7 Days
BUDDY Price Down 36.7% Over Last 7 Days
Zacks: Analysts Expect Regency Centers Corp  Will Post Quarterly Sales of $274.40 Million
Zacks: Analysts Expect Regency Centers Corp Will Post Quarterly Sales of $274.40 Million
Analysts’ Weekly Ratings Updates for Pentair
Analysts’ Weekly Ratings Updates for Pentair


 
© 2006-2019 Zolmax.